Physician profile
John S Henry
NPI 1831157213
$78,888.46
in general payments reported to CMS, 2019-2025
49 companies · $10K in 2025
The $10K reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,653 · 2021: $11K · 2022: $12K · 2023: $17K · 2024: $5,839 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $8,986 · Travel and Lodging: $3,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,302.50 |
| Food and Beverage | $8,985.55 |
| Travel and Lodging | $3,891.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66,122.70 | 2019-2025 | Repatha, Repatha, Tezspire |
| Novartis Pharmaceuticals Corporation | $1,757.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,452.95 | 2019-2025 | Camzyos, Eliquis, Coumadin |
| Astrazeneca Pharmaceuticals LP | $1,026.11 | 2019-2025 | Wainua, Lokelma, Farxiga |
| Pfizer INC. | $985.07 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $887.72 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.04 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $609.98 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $585.29 | 2019-2024 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $505.56 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $504.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $484.21 | 2022-2025 | Verquvo |
| Bridgebio Pharma, INC. | $457.32 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $429.01 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Scpharmaceuticals INC. | $324.79 | 2024-2025 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.